[go: up one dir, main page]

WO2013054147A3 - Sels d'erlotinib - Google Patents

Sels d'erlotinib Download PDF

Info

Publication number
WO2013054147A3
WO2013054147A3 PCT/HU2012/000102 HU2012000102W WO2013054147A3 WO 2013054147 A3 WO2013054147 A3 WO 2013054147A3 HU 2012000102 W HU2012000102 W HU 2012000102W WO 2013054147 A3 WO2013054147 A3 WO 2013054147A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid salt
erlotinib
erlotinib salts
mandelic
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HU2012/000102
Other languages
English (en)
Other versions
WO2013054147A2 (fr
Inventor
Ede MÁRVÁNYOS
Gábor NÉMETH
Balázs VOLK
László Pongó
József Barkóczy
András DANCSÓ
Mónika MEZŐVÁRI
Zoltán VARGA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egis Pharmaceuticals PLC
Original Assignee
Egis Pharmaceuticals PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Pharmaceuticals PLC filed Critical Egis Pharmaceuticals PLC
Priority to EA201490773A priority Critical patent/EA201490773A1/ru
Priority to EP12826647.5A priority patent/EP2776406A2/fr
Priority to BR112014008733A priority patent/BR112014008733A2/pt
Priority to CN201280058335.8A priority patent/CN103958483A/zh
Publication of WO2013054147A2 publication Critical patent/WO2013054147A2/fr
Publication of WO2013054147A3 publication Critical patent/WO2013054147A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des sels d'erlotinib sélectionnés dans le groupe comprenant sel d'acide maléique, sel d'acide salicylique, sel d'acide L-mandélique, sel d'acide adipinique, sel d'acide 1,5-naphtalène-disulfonique, sel d'acide L-pyroglutamique, sel d'acide 1-Hydroxy-2-naphtoïque, et sel d'acide mandélique et des formes amorphes et cristallines, des hydrates et des solvates de ceux-ci. Les sels d'erlotinib de la présente invention sont utiles en thérapie, en particulier pour le traitement ou la prophylaxie du cancer du poumon non à petites cellules et du cancer du pancréas.
PCT/HU2012/000102 2011-10-10 2012-10-10 Sels d'erlotinib Ceased WO2013054147A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EA201490773A EA201490773A1 (ru) 2011-10-10 2012-10-10 Соли эрлотиниба
EP12826647.5A EP2776406A2 (fr) 2011-10-10 2012-10-10 Sels d'erlotinib
BR112014008733A BR112014008733A2 (pt) 2011-10-10 2012-10-10 sais de erlotinib
CN201280058335.8A CN103958483A (zh) 2011-10-10 2012-10-10 厄洛替尼盐

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1100562A HU230483B1 (hu) 2011-10-10 2011-10-10 Erlotinib sók
HUP1100562 2011-10-10

Publications (2)

Publication Number Publication Date
WO2013054147A2 WO2013054147A2 (fr) 2013-04-18
WO2013054147A3 true WO2013054147A3 (fr) 2013-06-13

Family

ID=89990469

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2012/000102 Ceased WO2013054147A2 (fr) 2011-10-10 2012-10-10 Sels d'erlotinib

Country Status (6)

Country Link
EP (1) EP2776406A2 (fr)
CN (1) CN103958483A (fr)
BR (1) BR112014008733A2 (fr)
EA (1) EA201490773A1 (fr)
HU (1) HU230483B1 (fr)
WO (1) WO2013054147A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014118737A1 (fr) * 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Sels d'erlotinib
CN104250230A (zh) * 2014-09-05 2014-12-31 亿腾药业（泰州）有限公司 厄洛替尼柠檬酸盐与其晶型以及它们的制备方法
CN116554111B (zh) * 2023-03-09 2025-09-12 湖北中医药大学 一种厄洛替尼共无定形物及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060691A2 (fr) * 2005-11-23 2007-05-31 Natco Pharma Limited Nouveau procede pour la preparation d'erlotinib
WO2010109443A1 (fr) * 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Procede de preparation d'erlotinib ou de ses sels pharmaceutiquement acceptables
WO2011068403A2 (fr) * 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Nouveaux sels de n-(3-éthynylphénylamino)-6,7-bis(2-méthoxyéthoxy)-4-quinazolinamine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2161290T3 (es) 1995-03-30 2001-12-01 Pfizer Derivados de quinazolina.
CN1298396A (zh) 1998-04-29 2001-06-06 Osi药物公司 N－(乙炔苯氨基)－6,7－双(2－甲氧基乙氧基)－4－喹唑啉胺甲磺酸盐无水物和一水合物
EP2139868B1 (fr) 2007-04-04 2015-07-29 Cipla Limited Procédé de préparation de l'erlotinib et de ses sels pharmaceutiquement acceptables

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060691A2 (fr) * 2005-11-23 2007-05-31 Natco Pharma Limited Nouveau procede pour la preparation d'erlotinib
WO2010109443A1 (fr) * 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Procede de preparation d'erlotinib ou de ses sels pharmaceutiquement acceptables
WO2011068403A2 (fr) * 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Nouveaux sels de n-(3-éthynylphénylamino)-6,7-bis(2-méthoxyéthoxy)-4-quinazolinamine

Also Published As

Publication number Publication date
EA201490773A1 (ru) 2014-10-30
WO2013054147A2 (fr) 2013-04-18
HUP1100562A2 (en) 2013-05-28
CN103958483A (zh) 2014-07-30
HU230483B1 (hu) 2016-07-28
EP2776406A2 (fr) 2014-09-17
BR112014008733A2 (pt) 2017-04-25

Similar Documents

Publication Publication Date Title
WO2014028600A3 (fr) Composés 3-aminocycloalkyl utilisés en tant qu'inhibiteurs de rorgammat et utilisations de ceux-ci
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
MX2020009397A (es) Composiciones y metodos para inhibicion de la via jak.
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
WO2012106534A3 (fr) Inhibiteurs de l'intégrase du vih
WO2011133795A3 (fr) Bêta-carbolines à titre d'inhibiteurs de kinases haspine et dyrk
PH12014500103A1 (en) Pyridin-2(1h)-one derivatives as jak inhibitors
TN2015000121A1 (en) Gdf-8 inhibitors
WO2012017239A3 (fr) Composés chimiques
IL236922A0 (en) Salts and solid forms of (4))-4)-3-(s-morpholinomethyl)benzyl)oxy)-1-oxoisoindoline-2-yl)piperidine-6,2-dione and compounds containing them and methods of their use
WO2012104007A3 (fr) Dérivés de 7-azaindole
WO2012122011A3 (fr) Amino-quinoléines en tant qu'inhibiteurs de kinase
MX395263B (es) Forma cristalina de base libre de lorlatinib
MX355088B (es) Inhibidores de tienopirimidina de proteina cinasa c atipica.
UA107865C2 (ru) Гетероциклические карбоксамиды
EA201300282A1 (ru) Производные триазолопиразина
WO2015082887A3 (fr) Utilisation d'inhibiteurs de kinases
EA024194B8 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
WO2013057013A3 (fr) Dérivés d'alcools 1-phényl-2-pyridinylalkyliques utilisés comme inhibiteurs de phosphodiestérase
WO2009094560A3 (fr) Thiénopyranones en tant qu'inhibiteurs de kinase
WO2012017321A3 (fr) Traitement de la dyslipidémie
WO2013054147A3 (fr) Sels d'erlotinib
WO2014049585A3 (fr) Procédé de préparation d'étéxilate de dabigatran ou d'un sel pharmaceutiquement acceptable de cette substance
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
WO2013155465A8 (fr) Dérivés de xanthine substituée

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12826647

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: A201404939

Country of ref document: UA

REEP Request for entry into the european phase

Ref document number: 2012826647

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012826647

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201490773

Country of ref document: EA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014008733

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014008733

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140410